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Abstract
Basal cell carcinoma (BCC) growth requires high levels of Hedgehog (Hh) signaling through the 
transcription factor Gli1. While inhibitors of membrane protein Smoothened (Smo) effectively 
suppress Hh signaling, early tumor resistance illustrates the need for additional downstream 
targets for therapy1–6. Here we identify atypical Protein Kinase C iota/lambda (aPKC) as a novel 
Gli regulator. aPKC and its polarity signaling partners7 colocalize at the centrosome and form a 
complex with Missing-in-Metastasis (MIM), a scaffolding protein that potentiates Hh signaling8,9. 
Genetic or pharmacological loss of aPKC function blocks Hh signaling and proliferation of BCC 
cells. aPKC is a Hh target gene that forms a positive feedback loop with Gli and exhibits elevated 
levels in BCCs. Genome-wide transcriptional profiling shows that aPKC and Smo control the 
expression of similar genes in tumor cells. aPKC functions downstream of Smo to phosphorylate 
and activate Gli1, resulting in maximal DNA binding and transcriptional activation. Activated 
aPKC is upregulated in Smo-inhibitor resistant tumors and targeting aPKC suppresses signaling 
and growth of resistant BCC cell lines. These results demonstrate aPKC is critical for Hh-
dependent processes and implicates aPKC as a new, tumor-selective therapeutic target for the 
treatment of Smo-inhibitor resistant cancers.
In order to identify new druggable targets in the Hh pathway, we used the scaffold protein 
MIM, which potentiates Gli-dependent activation downstream of Smo9, as bait in a biased 
proteomics screen of factors involved in Hh signaling and ciliogenesis. Two of the hits were 
polarity proteins not previously linked to the Hh pathway: aPKC, a serine-threonine kinase, 
and Pard3, a scaffold protein and aPKC substrate (Supplementary Fig. 1a). Reciprocol 
immunoprecipitation of aPKC and Pard3 pulled down MIM suggesting a specific interaction 
(Supplementary Fig. 1b). As MIM is a centrosome-associated protein that promotes 
ciliogenesis8, we fractionated centrosomes and found aPKC, along with Pard3 and Pard6A, 
cofractionated and coimmunoprecipitated with MIM in gamma-tubulin positive fractions 
that mark centrosomes (Fig. 1a; Supplementary Fig. 1c). MIM partially colocalizes with 
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aPKC complex members at the basal body in dermal fibroblasts, keratinocytes, and the well-
characterized mouse BCC cell line ASZ00110 (Fig. 1b), where aPKC and MIM interact 
through coimmunoprecipitation (Fig. 1c). Loss of aPKC or MIM protein suppresses Hh 
signaling as mRNA levels of Hh target gene gli1 was reduced and ciliogenesis was inhibited 
(Fig. 1d,e; Supplementary Fig. 1d,e).
As aPKC kinase activity is necessary for many of its cellular functions7,11, we used a 
myristoylated aPKC peptide inhibitor (PSI) to suppress kinase activity12 (Supplementary 
Fig. 1f). PSI, but not a myristoylated scrambled peptide, inhibited Hh signaling in BCC cells 
in a dose-dependent manner similar to the Smo antagonist cyclopamine (Fig. 1f). PSI, a pan 
PKC inhibitor Go6983, or genetic loss of aPKC expression, also resulted in a dose-
dependent inhibition of cell growth in BCC cells, leading to cell death as assayed by the 
MTT assay (Fig. 1g and Supplementary Fig. 1g,h). PSI inhibited BCC cell growth at a 
concentration similar to that of cyclopamine, with an IC50 of 5uM. Primary cilia were 
reduced by 50% in PSI-treated BCC cells (Fig. 1e) indicating aPKC activity is critical to 
both Hh signaling and ciliogenesis in BCC cells. Interestingly, PSI did not affect 
proliferation in several non-tumorigenic cells (Supplementary Fig. 1i). PSI specifically 
inhibited aPKC as loss of aPKC in BCC cells in combination with PSI treatment possesses 
no additional activity to reduce levels of gli1 or apkc mRNA (Supplementary Fig. 1j).
To address whether aPKC’s effect on the Hh pathway is direct, we assayed aPKC function 
in several nonpolar cell lines (Supplementary Fig. 1k,l; not shown). These cells maintained 
or increased their primary cilia after aPKC knockdown, however, aPKC removal still 
blocked Hh activation, reducing target gene induction. We conclude that aPKC’s effects on 
Hh signaling are cilia-independent and required for maximal sustained signaling.
As aPKC is necessary for maximal Hh signaling, we next asked if aPKC is overexpressed in 
BCCs. Indeed, apkciota expression, but not apkczeta, is specifically upregulated with gli1 in 
BCC cells (Fig. 2a). Similar results are found using freshly isolated human BCCs compared 
to primary human keratinocytes (Fig. 2b). Immunohistochemical staining of human BCCs 
and normal skin with antibodies recognizing both total and activated aPKC (P-aPKC) show 
higher levels in invasive and nodular tumors, with P-aPKC showing greater overexpression 
(Fig. 2c; 4h). Loss of aPKC removes both aPKC and P-aPKC staining in primary mouse 
dermal cells, indicating the specificity of the antibody (Supplementary Fig. 2).
As aPKC and Hh signaling are required for BCC cell growth, we next asked whether aPKC 
is a Hh target gene. Activation of Hh signaling in both polarized and non-polarized primary 
and immortalized cells using Shh-N ligand induces both gli1 and apkciota transcripts (Fig. 
2d). Additionally, when we block Hh signaling by treating BCC cells with cyclopamine, gli1 
and apkciota transcripts, but not apkczeta, are specifically suppressed (Fig. 2g). Three 
putative Gli1 binding sites13 are present in the promoter region within 5 kb of the apkciota 
transcriptional start site in mice (Fig. 2e). Chromatin immunoprecipitation (ChIP) with BCC 
cells overexpressing Flag:Gli1 enrich in regions containing the three Gli1 binding sites (Fig. 
2f) indicating that aPKC is a direct target of Gli1. The first two Gli1 binding sites promote 
expression of luciferase when expressed in BCC cells suggesting these sites are functional 
(Supplementary Fig. 3). In addition, expression of pard6a (aPKC inhibitor) is reduced 
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whereas cdc42 (activator) is overexpressed in primary mouse BCC tumors14 (Fig. 2h). As 
aPKC is typically found in an inhibited Pard6A complex, less Par6A would result in 
excessive free and active aPKC whereas more Cdc42 would activate any existing Pard6A-
aPKC complexes. Interestingly, when Hh signaling is inhibited with the Smo antagonist 
Sant-1, pard6a transcript levels are elevated and cdc42 levels are repressed (Fig. 2i) further 
supporting the idea that Hh signaling promotes aPKC activation. We conclude that aPKC is 
part of a Hh-mediated positive feedback loop leading to its overexpression in human and 
mouse BCCs.
To gain insight into aPKC’s mechanism of action, we determined whether aPKC-dependent 
genes in tumors differed from those regulated by Smo. We treated BCC cells with Sant-1 or 
PSI and performed 3’-end polyadenylated RNA sequencing. 5700 Sant-1-dependent or 4762 
PSI-dependent transcripts changed two-fold or greater when compared to control (Fig. 3a). 
4325 transcripts overlapped between the inhibitor-treated data sets (p<1.0×10−300) with 
most transcripts downregulated in both sets (Fig. 3b). Gene ontology terms associated with 
commonly changed transcripts include cell cycle regulation, protein transport and 
localization, and cell division (Fig. 3c). Global transcript expression regardless of fold-
change showed a strong positive correlation, with a Pearson correlation of 0.495. 
Comparision with previously published Hh-dependent data sets from mouse 
medulloblastomas/granular neural precursors (GNPs) or developing mouse limb bud15,16 
reveals substantial overlap (Supplementary Fig. 4a). 321 of the 1077 Gli1 binding sites 
found in medulloblastomas/GNPs (p=1.36×10−11) and 41 out of 396 (p=8.92×10−9) Gli3 
binding sites identified in the developing limb bud overlap with our commonly changed data 
set. Representative gene expression profiles among the data sets are displayed in a cluster 
heat map (Supplementary Fig. 4b). Validation of a subset of transcript expression levels 
using quantitative RTPCR shows that the relative values from our data set closely mirror 
actual mRNA levels upon drug treatment (Supplementary Fig. 4c,d). These results indicate 
that aPKC and Smo regulate a common set of Hh target genes in BCCs.
The striking overlap of transcriptional targets suggested that aPKC might regulate Gli 
transcription factors. To determine where aPKC acts, we added subthreshold concentrations 
of cyclopamine or PSI to BCC cells. We found only cyclopamine outcompeted SAG-
mediated activation (Supplementary Fig. 5a), indicating aPKC functions downstream of 
Smo. Moreover, aPKC inhibition modestly increases rather than decreases Gli1 stability 
(Supplementary Fig. 5b), does not affect Gli2 or Gli3 processing (Supplementary Fig. 5c), 
and does not alter Gli1 nuclear localization (Fig. 3d; Supplementary Fig. 5d), suggesting that 
aPKC affects Gli activity. Intriguingly, loss of aPKC in mouse fibroblasts results in a Gli1 
band with slightly smaller apparent molecular weight (Supplementary Fig. 5e,f). By 
contrast, loss of MIM, despite primary cilia defects that prevent significant activation of the 
Hh pathway8, have more aPKC protein and a Gli1 band with a slightly larger molecular 
weight, suggesting aPKC modifies Gli1 posttranslationally.
Consistent with the notion of aPKC-dependent alteration of Gli1 activity, aPKC and Gli1 
form a complex as recombinant HIS:aPKC and in vitro translated (IVT) human HA:Gli1 or 
HA:Gli1 zinc finger coimmunoprecipitate (Fig. 3e). Purified aPKC directly phosphorylates 
Gli1 in vitro (Fig. 3f), with the majority of the phosphorylation occurring in the zinc finger 
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DNA binding region of Gli1. Immunoprecipitation of endogenous Gli1 from BCC cells 
shows PSI-dependent phosphorylation at serine/threonine residues, further supporting an in 
vivo role for aPKC (Fig. 3g). PSI-treated IVT human Gli1:V5/HIS, where endogenous aPKC 
is inhibited in the reaction, significantly reduced binding to radiolabeled Gli1 target DNA in 
an electrophoretic mobility assay (Fig. 3h,i). Addition of recombinant aPKC overcame the 
effects of PSI to rescue Gli1-dependent DNA binding, whereas heat-inactivated aPKC did 
not (Supplementary Fig. 5g), indicating Gli1 phosphorylation by aPKC is necessary for 
maximal DNA binding. The phosphorylation state of Gli1 appears critical as higher 
concentrations of aPKC leads to paradoxically decreased DNA binding (Supplementary Fig. 
5g). We performed a mutagenesis screen of the DNA binding domain to determine the site 
of aPKC phosphorylation and found that residues S243 and T304 appear to mediate aPKC 
effects. Phospho-mimetic Gli1 (Gli1S243E,T304E) bound to target DNA just as well as wild-
type Gli1, whereas phospho-deficient Gli1 (Gli1S243A,T304A), which accumulates less aPKC 
phosphorylation (Supplementary Fig. 5h), has reduced DNA binding ability (Fig. 3h,i). 
Moreover, Gli1S243E,T304E possesses reduced sensitivity to PSI in BCC cells, suggesting 
these sites are functional aPKC sites (Fig. 3j). To confirm aPKC regulates Gli binding in 
vivo, we performed ChIP of Flag:Gli1 in BCC cells using Gli target genes17,18. On all Gli1 
targets assayed, PSI-treated tumor cells left Gli1 nuclear protein levels unchanged but 
reduced the association with chromatin (Fig. 3d,k). Non-Hh target genes were left 
unchanged by PSI treatment. We conclude that aPKC regulates Hh signaling by 
phosphorylating and activating Gli1 to increase its affinity for DNA, illustrating a rare 
instance where posttranslational modification of a zinc-finger domain promotes DNA 
binding and transcriptional activity.
To explore whether aPKC inhibitors can be used successfully as a BCC therapeutic, we 
topically treated allografted BCC tumors14 with PSI. This tumor model faithfully reflects 
human BCCs and has previously been used to validate Hh pathway inhibitors now in clinical 
use19. In allografted BCCs, gli1 mRNA was reduced with increasing concentrations of 
topical PSI (Fig. 4a). Tumor size was also suppressed with intermediate concentrations of 
PSI with no apparent acquired resistance (Fig. 4b), comparing favorably with treatment of 
intermediate concentrations of Smo antagonist itraconazole19 or Gli2 inhibitor arsenic 
trioxide20 (Fig. 4c). Tumors lost their classical palisade patterning upon PSI treatment and 
apoptosis increased (Supplementary Fig. 6). Cell proliferation was reduced along with Gli1 
protein levels. Mice treated with topical or intraperitoneal PSI displayed no apparent adverse 
effects (Supplementary Fig. 7) except a mild hair cycling phenotype (not shown) suggesting 
aPKC treatment is tumor-selective.
Because aPKC acts downstream of Smo, we determined whether PSI could inhibit cell 
growth of Smo-resistant tumors. Following methods to generate resistant lines for other 
chemotherapeutics like K-ras or B-raf21, we generated multiple independent BCC cell lines 
that were resistant to high levels of Sant-1. These Smo-resistant lines displayed increased 
expression of apkc mRNA and protein, with varying levels of gli1 mRNA (Fig. 4d; 
Supplementary Fig. 8a). Other Hh target genes displayed differential expression patterns that 
followed gli1 or apkc mRNA levels, or were generally suppressed (Supplementary Fig. 8b). 
We verified Smo resistance by treating the cells with high concentrations of structurally 
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unrelated cyclopamine and found little effect on cell proliferation (Fig. 4e). Treatment of 
these lines, or Sant-1 sensitive parental lines, with PSI dramatically reduced cell 
proliferation, suggesting active aPKC plays a role in Smo inhibitor-resistant human tumors. 
Comparison of Smo inhibitor-sensitive and resistant locally invasive human BCCs, several 
of which lacked Smo and Sufu mutations as well as Gli1/2 amplification (B. Yauch, 
personal communication), displayed elevated levels of active aPKC with polyclonal and 
monoclonal antibodies, corroborating the increase of active aPKC levels as a mode of 
resistance (Fig. 4f,g; Supplementary Fig. 8c,d). Taken together, these data argue that BCCs 
become dependent on aPKC to drive Hh activation and tumor growth, and suppression of 
aPKC activity is sufficient to prevent BCC progression in both Smo sensitive and resistant 
lines. Our results highlight aPKC inhibition as a viable, tumor-selective alternative to Smo 
inhibitors to treat Hh-dependent and Smo-resistant cancers.
Full Methods
Tumor immunofluorescence
Human tumors from Smo inhibitor sensitive and resistant patients were obtained from 
patients enrolled in clinical trials performed by the Stanford group (AEO, JYT), clinical 
trials NCT00833417 and NCT00957229. Patients were consented under an approved 
Stanford IRB protocol (#18325). Active and total aPKC levels in human tumor sections 
were determined by immunofluorescence using rabbit anti-aPKC (1:250; Santa Cruz 
Biotechnology), rabbit anti-p-aPKC Thr 410 (1:100; Santa Cruz Biotechnology), or mouse 
anti-p-aPKC Thr 410 (1:100; Santa Cruz Biotechnology). Confocal images were acquired on 
a Leica SP2 AOBS Laser Scanning Microscope with a HCX PL APO 63× oil immersion 
objective. Average pixel intensity over five distinct areas per tumor section was determined 
using ImageJ. Images were arranged with ImageJ, Adobe Photoshop, and Adobe Illustrator.
Cell culture
Primary mouse dermal cells were isolated as previously described8. Dermal cells were 
grown in Amniomax media containing supplement and antibiotics (Invitrogen). ASZ001 
cells were grown in 154CF media containing 2% chelated FBS, HKGS supplement, and 
antibiotics (Invitrogen). Keratinocytes (HPA Culture Collections) were grown in CnT-07 
media containing supplement and 0.07mM CaCl2 (CellNTec). Cells were sterum-starved 
between 24–48 hrs to induce ciliogenesis. MTT cell proliferation assay was performed using 
manufacturer’s protocol from Invitrogen. Cells were transfected with FuGene6 or 
nucleofected with Amaxa Human Keratinocyte Nucleofector kit using manufacturer’s 
protocol.
Smo resistant cell lines were generated by treating ASZ001 BCC cells with increasingly 
higher concentrations of Sant-1 every passage for three weeks. Final resistant cell lines were 
grown in 60uM Sant-1. Cyclopamine was used to inhibit Hh signaling to verify Smo 
resistance.
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Antibodies and immunofluorescence staining
Cells were fixed with either 4% paraformaldehyde or 100% methanol for 10 min. 1% 
normal horse serum and 0.1% Triton X-100 in PBS was used for blocking. Tissues were 
fixed with 4% paraformaldehyde and embedded in paraffin. 10um sections were cut and 
deparaffinized using standard conditions before staining. Tissue sections were blocked using 
20% normal horse serum and 0.1% Triton X-100 in PBS. The following antibodies were 
used: rabbit anti-aPKC (1:500; Santa Cruz Biotechnology), rabbit anti-p-aPKC Thr 410 
(1:100; Santa Cruz Biotechnology), mouse anti-p-aPKC Thr 410 (1:100; Santa Cruz 
Biotechnology), rabbit anti-Pard6a (1:100; Santa Cruz Biotechnology), mouse anti-Pard6a 
(1:100; Santa Cruz Biotechnology), mouse anti-Pard3 (1:500; Millipore), mouse anti-Cdc42 
(1:500; Santa Cruz Biotechnology), rabbit anti-MIM (1:1000)8, rabbit anti-γ-tubulin (1:500; 
Sigma), mouse anti-γ-tubulin (1:500; Abcam), mouse anti-acetylated tubulin (1:2000; 
Sigma), goat anti-Gli2 (1:500; R&D Systems), goat anti-Gli3 (1:250; R&D Systems), rat 
anti-HA (1:1000, Covance), rabbit anti-KI67 (1:200; Lab Vision), mouse anti-Gli1 (1:1000; 
Cell Signaling), rabbit anti-phosphoserine/threonine (1:1000; Abcam), mouse anti-actin 
(1:5000; Sigma), rabbit anti-HSP90 (1:200; Santa Cruz Biotechnology), mouse anti-p63 
(1:200; Santa Cruz Biotechnology), and TUNNEL stain (Roche). Secondary antibodies were 
from Invitrogen. Confocal images were acquired on a Leica SP2 AOBS Laser Scanning 
Microscope with a HCX PL APO 63× oil immersion objective. Images were arranged with 
ImageJ, Adobe Photoshop, and Adobe Illustrator.
Protein purification and binding experiments
All proteins were expressed and purified as previously described22. In vitro translated 
proteins were produced using manufacturer’s protocol in rabbit reticulocyte lysate from 
Promega. Endogenous proteins were immunoprecipitated by using 5ug rabbit anti-aPKC, 
chicken anti-MIM, mouse anti-Pard3, rabbit anti-Pard6a, rat anti-HA, mouse anti-Gli1, or 
mouse anti-Flag (Sigma) with protein A/G-conjugated beads according to the 
manufacturer’s protocol (Santa Cruz Biotechnology). In vivo phosphorylated Gli1 detected 
by immunoprecipitation of Gli1 from BCC cells treated with 10uM MG132 in the presence 
or absence of 10uM PSI for 6 hrs. Samples were separated by SDS-PAGE and transferred to 
nitrocellulose, followed by antibody incubations and visualization using chemiluminescent 
substrate (ThermoScientific).
Centrosomes were purified from mouse C3H 10T1/2 cells as previously described23. 
Supernatant fractions isolated by incubation of mouse BCC cells with lysis buffer (10mM 
HEPES pH 7.5, 1.5mM MgCl2, 10mM KCl, 0.4% NP-40) for 2 min on ice. Nuclei were 
spun down and washed twice with lysis buffer before equal volume resuspension in PBS and 
addition of SDS loading buffer.
Kinase assays
HIS:aPKC (Abcam) was incubated with GST, GST:Gli1, or GST:Gli1 fragments at 30°C for 
15 min in kinase reaction buffer (20mM Tris-HCl pH 7.5, 10mM MgCl2, 1mM DTT, 10mM 
ATP) with 20nM [□-32P]ATP. The reaction was quenched by addition of SDS loading 
buffer and heated at 95°C for 10 min. The protein was resolved by SDS-PAGE and exposed 
to a phosphor screen (Molecular Dynamics) and imaged with GE Typhoon 9410.
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ASZ001 cells were nucleofected (Amaxa) with pGL3-Basic (Promega) containing the 
following Gli binding sites or mutant sites multimerized (6×) head-to-tail: site 1 
(GACCCCCAA); site 1 mutant (GAAACACAG); site 2 (TGCCCCCCA); site 2 mutant 
(TGAACACCT); site 3 (TACCCCAAA); site 3 mutant (TAAACATAG); glics 
(GACCACCCA); glics mutant (GATAATCCG). Nucleofected cells were grown to 
confluency, lysed, and luciferase expression was determined using the Dual-Luciferase 
Assay System (Promega) and a TD-20/20 Luminometer.
Lentiviral knockdown and drug treatments
Lentiviral pLKO.1 vector containing short hairpin RNAs (Open Biosystems) to prkci 
(sh3:CCGTTCACCATGAAATGGATA, sh5:CCAGACAGAAAGCAGGTTGTT), or 
pSicoR-puro vector containing shRNA to MIM8 were used. Lentivirus containing empty 
vector pSicoR-puro was used for control knockdowns. Lentiviral infection was performed 
and cells assayed after three days for prkci shRNA and four days for MIM shRNA. Protein 
knockdown was confirmed by western blot or qRTPCR.
Drug treatments for cells were performed with myristoylated PSI (myr-
SIYRRGARRWRKLY), myristoylated scramble peptide (myr-RGIRYRLRARSWK), 
Sant-1 (Tocris Bioscience), cyclopamine (Tocris Bioscience), SAG (EMD), Go6983 (Tocris 
Bioscience), and cyclohexamide (Sigma). Subconfluent ASZ001 cells were serum-starved 
and inhibitors added for 48 hrs prior to MTT assay (Invitrogen) and 24 hrs prior to visualize 
cilia and assay Gli target gene induction. Stability assays performed with ASZ001 
preincubated with PSI for one hour before 20ug/ml cyclohexamide addition at various time 
points. Mouse blood parameters were tested by treating mice topically twice daily with 
DMSO or 0.8mg/kg PSI dissolved in DMSO for 3 days.
Chromatin immunoprecipitation
Protein-DNA complexes were captured by fixing ASZ001 cells expressing Flag:Gli1 and 
preincubated 24 hrs with inhibitors, fixed for 10 min with 1% formaldehyde, and quenched 
with 0.125M glycine for 5 min. ChIP was performed using manufacturer’s protocol adapted 
from Upstate. Briefly, cells were lysed for 10 min at 4°C in lysis buffer (50mM Hepes 
pH7.5, 140mM NaCl, 1mM EDTA, 10% glycerol, 0.1% NP-40, 0.2% Triton-X100, protease 
inhibitors [Roche]) and nuclei were pelleted and lysed for 10 min at 4°C in nuclei lysis 
buffer (10mM Tris-HCl pH 8, 100mM NaCl, 1mM EDTA, 0.5mM EGTA, 0.5% N-
lauroylsarcosine, protease inhibitors) to obtain DNA. DNA was sheared to a range of 100–
600bp in size by sonicating for 25 min. ChIP-grade Flag antibody-conjugated magnetic 
beads (Sigma) was incubated with nuclei lysate overnight at 4°C. Beads were washed in 
RIPA buffer and DNA was reverse crosslinked by incubation at 65°C overnight in elution 
buffer (50mM Tris-HCl pH8, 10mM EDTA, 1% SDS). RNA and protein was digested with 
RNase A (0.2ug/ml; 37°C for 2 hrs) and proteinase K (0.2ug/ml; 55°C for 2 hrs), 
respectively, and DNA purified by phenol chloroform extraction using standard protocols. 
Relative fold enrichment was determined by adding DNA to Brilliant II SYBR Green qPCR 
Master Mix Kit (Agilent Technologies) containing primers to known Gli target sites listed in 
Atwood et al. Page 7









Supplementary Table 1. ChIP with Flag antibody-conjugated magnetic beads in ASZ001 
without Flag:Gli1 was used as a negative control.
3’ end RNA sequencing
Library was generated from ASZ001 cells incubated with or without inhibitors for 24 hrs. 
RNA purified using TRIzol (Invitrogen) and poly A-RNA selected using the micro-
poly(A)purist kit (Ambion). Heat-sheared 200ng mRNA for 12 min at 85°C and performed 
first-strand cDNA synthesis using Superscript III (Invitrogen) for 1 hr at 50°C. Second-
strand synthesis was performed using E. coli DNA Ligase (Invitrogen), E. coli DNA 
Polymerase I (NEB), and E. coli RNAse H (Epicentre) for 2 hr at 16°C. Added T4 DNA 
Polymerase (NEB) for an additional 15 min before quenching with EDTA. Purified double-
stranded cDNA with MinElute Reaction Cleanup Kit (Qiagen). 3’ A-tailed using Klenow 
Fragment 3’ to 5’ exonuclease (NEB) for 30 min at 37°C. Ligated Illumina linker using T4 
DNA Ligase (Enzymatics) overnight at room temperature. Purified 220–300bp bands using 
3% NuSieve GTG agarose (Lonza) and MinElute Gel Extraction Kit (Qiagen). Amplified 
the DNA using Phusion PCR Master Mix (NEB) and 15 cycle PCR program. Purified 220–
300bp bands using 3% NuSieve GTG agarose (Lonza) and MinElute Gel Extraction Kit. 
Sequenced DNA using Illumina Genome Analyzer IIx.
Aligned 36 bp raw reads with Bowtie using the NCBI37/mm9 reference genome. 
Differential expression analysis was performed on the 3’ exon with the Cufflinks suite using 
mouse RefSeq gene predictions as a reference transcriptome. Annotated coding transcripts 
were filtered for significant expression by a RPKM of 25 in at least one sample set. 
Transcripts that were two-fold or greater changed in drug-treated samples were 
hierarchically clustered using the Cluster program and visualized in Java Treeview. 
Transcripts were validated using Brilliant II SYBR Green qRT-PCR Master Mix Kit 
(Agilent Technologies) with primers listed in Supplementary Table 1. Two-tail p-value 
between our gene sets and other gene sets calculated using Fisher’s Exact Test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. aPKC is a centrosome-associated protein that regulates Hh signaling
a, MIM and aPKC interact in purified centrosomes. b, MIM and aPKC complexes localize 
at the centrosome (γ-tub) versus primary cilia (Actub) of mouse dermal cells (mDC), mouse 
keratinocytes, and mouse BCC cells. Actub, acetylated tubulin. γ-tub, γ-tubulin. c, MIM and 
aPKC interact in BCC cells. d–f, gli1 mRNA levels (n=3) or cilia percentage (n=3) after 
MIM or aPKC shRNA, or aPKC or Smo inhibition in BCC cells. sh, short-hairpin. KD, 
knockdown. g, Cell proliferation reduced in BCC cells (n=3) after PSI or cyclopamine 
treatment, but not myristoylated scrambled peptide. Error bars, s.e.m.
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Figure 2. aPKC and Hh form a positive feedback loop in BCCs
a, b, gli1, aokciota, or apkczeta mRNA levels in (a) mouse BCC cells (n=3) and (b) primary 
human BCC tumors (n=7). c, Total and activated aPKC (P-aPKC) overexpressed in primary 
human BCC tumors. d, apkciota is upregulated in Shh-N-treated mouse dermal cells (n=3). 
CM, conditioned media. e, Gli1 binding sites within the promoter region of aPKC. TSS, 
transcriptional start site. f, Flag:Gli1 ChIP of aPKC promoter Gli1 sites. g, Cyclopamine 
suppresses apkciota expression in BCC cells (n=3). h, pard6a expression is reduced and 
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cdc42 is upregulated in mouse BCC tumors (n=3). i, Sant-1-treatment of BCC cells 
increases pard6a and decreases cdc42 mRNA expression (n=3). Error bars, s.e.m.
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Figure 3. aPKC phosphorylates and activates Gli1
a, Venn diagram and (b) heatmap of significantly changed transcripts upon Sant-1 or PSI 
treatment in BCC cells. c, Gene ontology terms of commonly altered transcripts. d, PSI does 
not affect nuclear Gli1 in BCC cells. e, aPKC interacts with in vitro translated (IVT) human 
Gli1 or Gli1 DNA-binding domain. f, aPKC phosphorylates human Gli1 DNA-binding 
domain. CBB, coomassie brilliant blue. g, PSI reduces phosphorylated serine/threonine 
levels of immunoprecipitated Gli1 from BCC cells. h, aPKC promotes DNA binding of IVT 
human Gli1 at S243 and T304 in an electrophoretic mobility shift assay (EMSA). NS, non-
specific binding. i, Densitometry of aPKC rescue, phosphomimetic versus phosphodeficient 
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Gli1 EMSA (n=3). j, BCC cells expressing phosphomimetic Gli1 show reduced PSI 
sensitivity (n=3). Error bars, s.e.m. k, Flag:Gli1 ChIP showing PSI and Sant-1 inhibit Gli1 
binding to target chromatin sites in mouse BCC cells.
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Figure 4. Topical aPKC inhibitor suppresses primary tumor growth
a, PSI inhibits Hh signaling in allografted mouse BCC tumors from Ptch1 +/−, K14CreER2, 
p53flox/flox mice (n=7). b, Topical treatment of allografted BCC tumors slows tumor 
growth (DMSO n=10, PSI n=9). c, Intermediate levels of PSI (n=8) compared to 
intermediate concentrations of Itraconazole (n=8) and arsenic trioxide (n=5). d, Five 
independently derived Smo-resistant BCC cell lines that amplify apkc or apkc and gli1 
mRNA levels (e) are sensitive to PSI treatment. f, g, Vismodegib-treated resistant human 
BCC tumors (n=6) display elevated levels of active aPKC compared to vismodegib-treated 
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sensitive tumors (n=8), non-drug treated tumors (n=17), and normal skin (n=7). Error bars, 
s.e.m.
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